|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
However, genotype frequencies of rs2596542A/G SNP were statistically different between HCV-induced HCC patients and controls (p = 0.048), and also between HCC and HCV-induced cirrhosis patients (p = 0.039).
|
31471884 |
2019 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Taken together our study suggest that MICA rs2596542 SNP impacts HCV-induced HCC susceptibility suggesting that genetic variants in MICA are of clinical relevance to hepatocarcinogenesis by impacting host immune response in chronic HCV infection.
|
31471884 |
2019 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Taken together our study suggest that MICA rs2596542 SNP impacts HCV-induced HCC susceptibility suggesting that genetic variants in MICA are of clinical relevance to hepatocarcinogenesis by impacting host immune response in chronic HCV infection.
|
31471884 |
2019 |
|
Hepatitis C, Chronic
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients.
|
31471884 |
2019 |
|
Hepatocarcinogenesis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Taken together our study suggest that MICA rs2596542 SNP impacts HCV-induced HCC susceptibility suggesting that genetic variants in MICA are of clinical relevance to hepatocarcinogenesis by impacting host immune response in chronic HCV infection.
|
31471884 |
2019 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The findings of this meta-analysis suggest that the rs2596542 variant in the MICA promoter region may affect MICA and soluble MICA (sMICA) protein expression, thereby influencing physiological vulnerability to HCC cells and the development of HCC.
|
31419949 |
2019 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
TT genotype at rs2596542 was a risk factor for the development of HCC in patients with HCV/HBV infection (OR = 1.248, 95% CI: 1.040-1.499, P = 0.017), particularly those with HCV infection (OR = 1.326, 95% CI: 1.101-1.599, P = 0.003) and Asians (OR = 1.273, 95% CI: 1.002-1.618, P = 0.048), or when the control group was patients with chronic hepatitis C (CHC) (OR = 1.506, 95% CI: 1.172-1.936, P = 0.001).
|
31419949 |
2019 |
|
Hepatitis B
|
|
0.020 |
GeneticVariation
|
BEFREE |
TT genotype at rs2596542 was a risk factor for the development of HCC in patients with HCV/HBV infection (OR = 1.248, 95% CI: 1.040-1.499, P = 0.017), particularly those with HCV infection (OR = 1.326, 95% CI: 1.101-1.599, P = 0.003) and Asians (OR = 1.273, 95% CI: 1.002-1.618, P = 0.048), or when the control group was patients with chronic hepatitis C (CHC) (OR = 1.506, 95% CI: 1.172-1.936, P = 0.001).
|
31419949 |
2019 |
|
Hepatitis C, Chronic
|
|
0.020 |
GeneticVariation
|
BEFREE |
TT genotype at rs2596542 was a risk factor for the development of HCC in patients with HCV/HBV infection (OR = 1.248, 95% CI: 1.040-1.499, P = 0.017), particularly those with HCV infection (OR = 1.326, 95% CI: 1.101-1.599, P = 0.003) and Asians (OR = 1.273, 95% CI: 1.002-1.618, P = 0.048), or when the control group was patients with chronic hepatitis C (CHC) (OR = 1.506, 95% CI: 1.172-1.936, P = 0.001).
|
31419949 |
2019 |
|
Pseudohyperkalemia Cardiff
|
|
0.010 |
GeneticVariation
|
BEFREE |
TT genotype at rs2596542 was a risk factor for the development of HCC in patients with HCV/HBV infection (OR = 1.248, 95% CI: 1.040-1.499, P = 0.017), particularly those with HCV infection (OR = 1.326, 95% CI: 1.101-1.599, P = 0.003) and Asians (OR = 1.273, 95% CI: 1.002-1.618, P = 0.048), or when the control group was patients with chronic hepatitis C (CHC) (OR = 1.506, 95% CI: 1.172-1.936, P = 0.001).
|
31419949 |
2019 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Nevertheless, we also detected significant associations between rs259</span>6542G>A and HCV-induced HCC</span>.
|
30967497 |
2019 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between MICA rs2596542 polymorphism and susceptibility to HCC.
|
30882647 |
2019 |
|
Hepatocarcinogenesis
|
|
0.020 |
GeneticVariation
|
BEFREE |
The C allele in MICA rs2596542 is a protective factor for hepatocarcinogenesis, whereas the T allele is a risk factor.
|
30882647 |
2019 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Recently, two GWAS variants, MICA rs2596542 and DEPDC5 rs1012068 were identified as being associated with the development of HCV-induced hepatocellular carcinoma (HCC) in Japanese patients.
|
30723271 |
2019 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Patients with the SNP rs2596542 A allele had significantly lower MICA expression in tumor tissue than did those with the GG genotype (24.7 ± 15.1% vs. 41.5 ± 23.4%, P < 0.001).
|
30361527 |
2018 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We enrolled 787 consecutive patients with chronic HCV infection, which included 174 cases of HCC, and 325 healthy subjects to clarify the involvement of HLA-Bw and C, KIRs, and major histocompatibility complex class I chain-related gene A (MICA) gene polymorphisms (rs2596542 and rs1051792) in chronic HCV infection and HCV-related HCC.
|
29731972 |
2018 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We enrolled 787 consecutive patients with chronic HCV infection, which included 174 cases of HCC, and 325 healthy subjects to clarify the involvement of HLA-Bw and C, KIRs, and major histocompatibility complex class I chain-related gene A (MICA) gene polymorphisms (rs2596542 and rs1051792) in chronic HCV infection and HCV-related HCC.
|
29731972 |
2018 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
These results demonstrate that MICA rs2596542G/G, and particularly the rs2596538C/C polymorphism, are associated with the risk of developing HCV-related HCC in a Sicilian population sample.
|
29584564 |
2018 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Finally, sMICA levels significantly increased during HCV-related liver disease progression, while a significant relationship between both rs2596542 and rs2596538 genotypes and sMICA plasma levels was identified in patients with LC and HCC.
|
29584564 |
2018 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, the MICA rs2596538 and rs2596542 variants warrant further research for their clinical validity and utility in relationship to the risk of developing HCV-related HCC in independent populations.
|
29584564 |
2018 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results demonstrate that MICA rs2596542G/G, and particularly the rs2596538C/C polymorphism, are associated with the risk of developing HCV-related HCC in a Sicilian population sample.
|
29584564 |
2018 |
|
Liver Cirrhosis
|
|
0.030 |
GeneticVariation
|
BEFREE |
Finally, sMICA levels significantly increased during HCV-related liver disease progression, while a significant relationship between both rs2596542 and rs2596538 genotypes and sMICA plasma levels was identified in patients with LC and HCC.
|
29584564 |
2018 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Recently, the MICA rs2596542 and DEPDC5 rs1012068 variants in Japanese individuals as well as the HCP5 rs2244546 and PNPLA3 rs738409 variants in European individuals have been found associated with hepatocellular carcinoma (HCC).
|
28928439 |
2017 |
|
Liver carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Genetic variants of MHC class I polypeptide-related chain A (MICA) at rs2596542 have been associated with hepatocellular carcinoma.
|
28427234 |
2017 |
|
Fibrosis, Liver
|
|
0.010 |
GeneticVariation
|
BEFREE |
Serum level and single nucleotide polymorphism at rs2596542 of MICA were tested for the association with liver fibrosis in 319 biopsy proven chronic hepatitis C patients.
|
28427234 |
2017 |